NEW YORK, N.Y. and LONDON, U.K. -- Campbell Belman, an established pharmaceutical analytics company, today introduces its new name: Eularis. This announcement reflects the significant growth the Company has achieved across its full range of pharmaceutical analytics products, which have helped tailor the advertising and marketing programs of its global top-tier clients.

NEW YORK, N.Y. and LONDON, U.K. -- Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation titled, "How to Tell if You Are Making the Right Research Decision for ROI - The Link Between Research and Decisions on Bottom Line Return."

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today their appreciation of the accomplishments of their contemporaries in 2007, a truly remarkable year in terms of biomedical research, scholarship, and gonzo journalism. It was a year in which a definitive meeting entitled "In Vivo Barriers to Gene Delivery" was held at the prestigious Cold Spring Harbor Laboratory, where Nobel laureate James Watson presides, or shall we say presided.

LONDON UK, and TOKYO Japan -- With the ever-increasing pressure to ensure maximum return on investment, sales force effectiveness is becoming a high priority...

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today the issue of U.S. Patent No. 7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company's leading anti-cancer agent, Rexin-G.

LONDON, U.K. -- Dr. Andree Bates, President of the Pharmaceutical analytics company Eularis, will be delivering a MasterClass on how to tell if you...

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today that the company has taken a major step toward the commercialization of its lead product with the opening of a Phase II Registration Protocol using Rexin-G for osteosarcoma in the United States. Following the accelerated approval of Rexin-G for the treatment of all solid tumors by the Bureau of Food and Drugs in the Philippines, Epeius opened a number of Phase I/II clinical trials.

SAN MARINO, Calif. -- Epeius Biotechnologies (www.epeiusbiotech.com) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out...

VINELAND, N.J. /eNewsChannels/ -- Designed for analytical research and clinical diagnostic testing, Laboratory Supply Distributors Corp. announces the 96-Well Multi-Tier™ Micro Plate System. Its unique, patented design allows for more flexibility and ease of use.

SAN MARINO, Calif. -- Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic pancreatic cancer (Chawla et...